Market Overview
Size, diversion, and installed base
- Brevintel analysis values the ileostomy market at USD 1.3 billion in 2025 ($1.3B), rising from about USD 1.4 billion in 2026 to USD 2.1 billion by 2035 at a 4.9% CAGR.
- Headline cards list $1.3B, $1.3B, and 4.9%; the matching 2035 card is retained even though the narrative also shows global value reaching USD 2,103 million by 2035.
- Coloplast led with over 37% share in 2025; Coloplast, ConvaTec Group, Hollister, B. Braun, and Smith+Nephew collectively held 81%.
- An ileostomy diverts intestinal output through a stoma created from the ileum, spanning one-piece and two-piece pouching systems plus barriers, rings, pastes, powders, removers, wipes, belts, and odor-control accessories.
- Unlike a one-time surgical device market, ileostomy care creates repeat demand because a permanent end ileostomy requires ongoing collection, adhesion, and skin-protection products.
- An estimated 13.5 million people worldwide live with a stoma, supporting a large installed base for recurring pouch and accessory consumption.
- Approximately 1.9 million new colorectal cancer cases were recorded in 2022, while more than 2.0 million new colorectal cancer cases were estimated in 2024.
- Ileostomies are used in selected colorectal cancer resections, severe inflammatory bowel disease procedures, and emergency bowel-diversion settings.
Care economics and accessory mix
- Brevintel analysis indicates the market expands on a stable installed-base model rather than procedure volumes alone, with permanent end ileostomies converting surgery into recurring consumption.
- Temporary loop ileostomies still create meaningful shorter-duration demand during colorectal and inflammatory bowel disease treatment pathways.
- The principal commercial boundary is peristomal skin performance: leakage, adhesive trauma, and poor fit can move a patient from loyal repeat use into switching or reduced adherence.
- Accessories are projected to grow at a 5.4% CAGR, faster than ostomy bags at 4.8%, functioning as a performance layer around core pouching systems rather than a replacement for them.
- End ileostomy generated USD 750.1 million in 2025, accounting for 57.5% of the market, and is projected to reach USD 1,250.6 million by 2035 at a 5.2% CAGR.
- Suppliers that combine barrier systems with fitting education, home-delivery support, and early leak-management tools are better placed to protect recurring revenue than those competing only on pouch price.
- Industry data suggests leakage prevention, skin preservation, and confidence in self-management are closely linked in ileostomy product selection.
- Value capture depends on whether products maintain a reliable seal against liquid, enzyme-rich ileostomy output after discharge into home care.
Market Dynamics
Epidemiology, aging, and product innovation
- GBD 2021 data recorded 375,140 new IBD cases globally in 2021, up 88.3% from 1990, while prevalent cases reached 3.83 million.
- China recorded the fastest increase in age-standardized IBD incidence in the underlying analysis, while India had the largest number of new IBD cases in 2021.
- A separate global analysis identifies Europe as having the highest pooled IBD prevalence, at 348.4 per 100,000 population.
- The global population aged 65 years and above totaled 833.5 million in 2024, and United Nations projections show that cohort rising from 761 million in 2021 to 1.6 billion by 2050.
- One in six people worldwide is expected to be aged 60 years or over by 2030, increasing exposure to colorectal cancer, bowel obstruction, ischemic colitis, and complex surgical care.
- China had 208.1 million people aged 65 years and above in 2024, while India had more than 100 million, supporting Asia Pacific's higher forecast growth.
- ConvaTec launched Esteem Body with Leak Defense in the United States in April 2024 and extended the platform to the UK in September 2024 after an earlier Italian introduction.
- Coloplast introduced Heylo, SenSura Mio Black, and SenSura Mio Convex Soft with Flex coupling during 2024, including sensor-based leakage notification at the barrier-skin interface.
- In the United States, Medicare Part B covers medically necessary ostomy supplies under the Prosthetic Device benefit, supporting replenishment for a large older patient cohort.
- Hollister's CeraPlus range positions ceramide-infused barriers around skin health and prevention of adhesive-related disruption, supporting premiumization when wear time improves.
Peristomal skin constraints
- Published evidence reports peristomal skin complication incidence ranging from 36.3% to 73.4% during the first 90 days after ostomy surgery.
- A multinational survey found that 88% of people living with an ostomy had experienced a peristomal skin complication, and 75% reported symptoms even without visible discoloration.
- In a study of recent ostomy patients, peristomal skin complications affected 47.5% of ileostomy patients during the first 90 days, compared with 36.1% of colostomy patients and 15.0% of urinary-diversion patients.
- Those complications were associated with higher 120-day readmission rates and higher healthcare costs, raising the commercial importance of seal integrity.
- Ileostomy patients face a distinctive risk profile because effluent is liquid and contains digestive enzymes that can rapidly damage skin when an appliance seal fails.
- The burden increases demand for rings, barrier films, convex systems, and protective accessories, but it can also generate dissatisfaction, switching, and payer scrutiny of premium systems.
- Brevintel analysis indicates epidemiological demand and device performance will determine different parts of market growth: IBD and aging expand the surgical population, while skin complications determine whether patients keep high-value routines after discharge.
- The restraint is most acute where patients leave hospital without access to trained stoma-care support, limiting the commercial effect of an improved adhesive if users cannot fit it correctly.
Segmentation Analysis
Type
- End ileostomy generated USD 750.1 million in 2025, accounting for 57.5% of the market, and is projected to reach USD 1,250.6 million by 2035 at a 5.2% CAGR.
- Its larger value reflects the durable consumption profile of permanent diversion, which creates a long-term need for bags, barriers, and skin-protection products.
- Loop ileostomy was valued at USD 405.8 million in 2025 and is forecast to reach approximately USD 645.6 million by 2035 at a 4.7% CAGR.
- These procedures are often intended to be temporary, particularly when protecting an anastomosis following colorectal surgery or restorative procedures for ulcerative colitis.
- High-output liquid effluent still makes a secure, skin-protective seal clinically demanding during the period of use.
- Other types represented USD 148.5 million in 2025 and are expected to expand at a 3.3% CAGR, reflecting more specialized clinical use.
Product
- Ostomy bags accounted for USD 1,083.7 million in 2025 and are projected to grow at a 4.8% CAGR.
- Two-piece systems represented USD 640.6 million and are expected to expand at a 5.0% CAGR, ahead of one-piece systems at USD 443.0 million and a 4.4% CAGR.
- The two-piece format allows a pouch to be changed without removing the skin barrier, which can be valuable for frequent pouch changes or vulnerable peristomal skin.
- One-piece systems remain important where simplicity, lower profile, and straightforward application are priorities, including advanced soft-convex one-piece designs.
- Accessories were valued at USD 220.7 million in 2025 and are forecast to expand at the fastest product CAGR of 5.4%.
- Accessory growth reflects a shift from optional add-ons toward using rings, films, and skin-care products to improve seal reliability, increasing revenue per patient in home care.
- Brevintel analysis suggests the most valuable segment shift is toward a more complete care system in which bags, barriers, accessories, fitting support, and follow-up reinforce one another.
Application
- Colorectal cancer represented the largest application segment at USD 479.2 million in 2025 and is projected to grow at a 5.2% CAGR.
- Product demand depends on tumor location, surgical approach, anastomotic risk, and whether diversion is temporary or permanent, not on an automatic ileostomy after every resection.
- Ulcerative colitis accounted for USD 333.7 million in 2025 and is forecast to grow at a 4.7% CAGR, including permanent end ileostomy or loop ileostomy associated with restorative surgery.
- Crohn's disease generated USD 267.8 million and is projected to expand at a 5.0% CAGR, including diversion in fistulizing, perianal, or recurrent disease settings.
- Other applications, including bowel obstruction, diverticulitis, ischemic colitis, trauma, and congenital conditions, represented USD 223.7 million and are expected to grow at a 4.2% CAGR.
End use
- Hospitals remained the largest end-use segment at USD 583.2 million in 2025, representing 44.7% of demand, and are forecast to grow at a 4.4% CAGR.
- Hospitals influence product choice at surgery, during inpatient recovery, and through initial stoma-care teaching, so institutional contracts and clinician education remain strategically important.
- Hollister's SURPASS sole-source contract with Premier illustrates the role of hospital-network access in establishing product availability at the point of first appliance teaching.
- Home care settings generated USD 501.9 million in 2025 and are projected to grow at the fastest end-use CAGR of 5.5%.
- Ambulatory surgical centers accounted for USD 132.8 million and are forecast to grow at a 5.1% CAGR, while other end users represented USD 86.5 million and are expected to expand at a 3.8% CAGR.
- Home care is projected to grow at 5.5%, above hospitals at 4.4%, moving more product decisions toward users who directly experience wear time, leakage, odor control, and skin comfort.
Regional Outlook
North America and Europe
- North America generated USD 251.1 million in 2025, representing 19.3% of the global market, and is forecast to grow at a 3.6% CAGR.
- The U.S. market was valued at USD 237.7 million in 2025, up from USD 228.4 million in 2024, and is projected to grow at a 3.4% CAGR.
- The U.S. has an estimated 2.4 million to 3.1 million adults living with IBD, while Medicare coverage for medically necessary ostomy supplies supports access for eligible users.
- Canada is expected to record a 5.3% CAGR, reflecting demand for consistent long-term management rather than a direct copy of U.S. channel strategies.
- Europe led the global market at USD 461.2 million in 2025 and is projected to expand at a 3.8% CAGR, combining mature ostomy-care infrastructure with the highest pooled regional IBD prevalence globally.
- Germany contributes through a large aging population and specialist surgical care; the United Kingdom is an important market for product innovation, including ConvaTec's Esteem Body with Leak Defence launch in September 2024.
- France forms part of Europe's high-prevalence IBD and colorectal-cancer care environment, with supplier success dependent on fitting support and product accessibility.
- Spain's role is shaped by colorectal and IBD management within a mature regional care setting, while Italy's older population supported an early 2024 launch market for ConvaTec's Esteem Body platform.
- The Netherlands remains relevant through its mature healthcare setting and the need for clinically supported, patient-centered stoma management.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific generated USD 425.8 million in 2025 and is expected to record the fastest regional CAGR of 6.2%.
- China has 208.1 million people aged 65 years and above and is identified as experiencing the fastest increase in age-standardized IBD incidence among the evaluated countries.
- Japan had 36.9 million people aged 65 years and above in 2024, supporting steady long-term demand for ease of use and skin compatibility among older users.
- India had one of the largest absolute numbers of new IBD cases in 2021 and a population of more than 100 million people aged 65 years and above.
- Australia participates through established colorectal cancer and IBD care demand; South Korea adds aging, specialist medical care, and expanding home-based management.
- Latin America was valued at USD 122.0 million in 2025 and is projected to grow at a 5.9% CAGR.
- Brazil is central to regional demand, with 23.4 million people aged 65 years and above; Mexico and Argentina add urban healthcare demand with more variable access and purchasing conditions.
- Middle East and Africa generated USD 44.3 million in 2025 and is forecast to grow at a 5.6% CAGR.
- Saudi Arabia and the United Arab Emirates are relevant Gulf markets for expanding surgical and specialized supply capacity, while South Africa is an important entry point for ileostomy care in sub-Saharan Africa.
- Brevintel analysis views Europe and North America as mature replacement and upgrade markets, while Asia Pacific and Latin America offer faster growth as disease burden, aging, and surgical access enlarge the long-term care base.
Competitive Landscape
Structure and recent developments
- The global ileostomy market is led by multinational companies with broad pouching portfolios, established clinical relationships, and access to hospital and home-care channels.
- Coloplast led with over 37% market share in 2025; the top five held 81%.
- Coloplast's Ostomy Care business reported 6% organic growth in FY2024/25 after 7% organic growth in FY2023/24, supported by Heylo, SenSura Mio Black, and SenSura Mio Convex Soft with Flex coupling.
- ConvaTec's Ostomy Care segment generated USD 634 million in 2024 and reported 5.3% organic growth, with Esteem Body with Leak Defense expanding the soft-convex one-piece offering.
- Hollister is differentiated by CeraPlus ceramide-infused barrier technology and institutional contracting, including a SURPASS sole-source contract with Premier for enterostomal therapy products.
- B. Braun offers ostomy appliance systems across ileostomy, colostomy, and urostomy care, including Flexima and Proxima product families.
- In June 2025, Eakin Healthcare announced a new ostomy bag production line at its Cardiff facility as part of a broader £60 million manufacturing investment program.
- The company described the 32-meter line as capable of increasing ostomy bag production capacity fourfold and reducing production waste relative to prior operations.
- ConvaTec launched Esteem Body with Leak Defense in the United States in April 2024 after an earlier Italian introduction, using Durahesive and Modified Stomahesive adhesive technologies in two convexity depths and four tension widths.
- Coloplast launched Heylo, SenSura Mio Black, and SenSura Mio Convex Soft with Flex coupling in May 2024, extending competition into digital leakage notification and discreet wear.
- Hollister subsequently received additional multi-year Premier contract agreements during 2024 to 2025, reinforcing group purchasing as a hospital initiation channel.
Integrated producers
- Coloplast
- ConvaTec Group
- Hollister
- B. Braun
- Smith+Nephew
Specialty suppliers
- Alcare
- Cymed Micro Skin
- Flexicare
- Marlen Healthcare
- Nu-Hope Labs
- Safe n Simple
- Salts Healthcare
- Torbot Group
- Welland Medical
- Unora Healthcare
- Eakin Healthcare